Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 8Breast Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pain 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × Genistein × Clear all
NCT01182246 2014-04-23

AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

Axcentua Pharmaceuticals AB

Phase 1/2 Unknown
44 enrolled
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡